VM206RY has shown activity against breast and ovarian tumors in preclinical studies.

Cobra Biomanufacturing will produce ViroMed’s VM206RY, a plasmid DNA treatment for tumors expressing Her2/neu. Cobrabio will manufacture ViroMed’s master cell bank and GMP-grade VM206RY for the first clinical trials, which will be held in Korea and in the U.S.

VM206 is an anticancer vaccine targeting Her2/neu-positive breast or ovarian cancer. The compound has shown in preclinical studies to elicit an immune response to Her-2, resulting in the reduction in the growth and the recurrence rate of breast or ovarian cancer.

Previous articleGenVec Enters Purchase Agreements for Common Stock and Warrants Worth $17M
Next articleQLT to Sell Acne Vulgaris Treatment to Allergan for $150M